{name}
{subtitle}
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~7 mi. (St Albans, Australia, +89 more cities)
facility
Sunshine Hospital
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +1 more drug
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~7 mi. (St Albans, Australia, +122 more cities)
facility
Western Health-Sunshine Hospital ( Site 3004)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~7 mi. (St Albans, Australia, +115 more cities)
facility
Sunshine Hospital
biomarker
ERBB2 Amplification, +7 more biomarkers
drug type
immunotherapy, +1 more type
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
city
~7 mi. (St Albans, Australia, +35 more cities)
facility
Western Health-Sunshine & Footscray Hospitals ( Site 0052)
drug
favezelimab, +1 more drug
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~8 mi. (Port Melbourne, Australia, +201 more cities)
facility
St Vincent's Hospital Melbourne /ID# 221809
drug
azacitidine, +1 more drug
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~9 mi. (Melbourne, Australia, +247 more cities)
facility
Peter MacCallum Cancer Centre
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~9 mi. (Melbourne, Australia, +147 more cities)
facility
Peter MacCallum Cancer Centre ( Site 0971)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~9 mi. (Melbourne, Australia, +140 more cities)
facility
Alfred Health ( Site 0004)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types